CHRCHR Posted - 12 hours ago

$PFE 🥱🚀 $SINT 🫵😎🚀 $PYPD ⏰🚀

CHRCHR Posted - 1 day ago

$PYPD +

sxpl Posted - 1 week ago

$PYPD $SLNA $JAGX

sxpl Posted - 1 week ago

$PYPD $LMAT Still death here ? The Simpsons Added both ☑️ https://www.defenseworld.net/2024/04/04/lemaitre-vascular-nasdaqlmat-vs-polypid-nasdaqpypd-head-to-head-contrast.html

Fredzel Posted - 2 weeks ago

$ACB $SNDL $RELI $PYPD

sxpl Posted - 2 weeks ago

$OCGN $ATOS $PYPD

CHRCHR Posted - 2 weeks ago

$PYPD https://www.marketbeat.com/stocks/NASDAQ/PYPD/

Fredzel Posted - 03/25/24

$PDD $PDLI $PYPD

sxpl Posted - 03/25/24

$PYPD time to get some snack, Zack 😎 https://finance.yahoo.com/news/polypid-ltd-pypd-upgraded-buy-170005880.html

sxpl Posted - 03/21/24

$PYPD it’s time …

CHRCHR Posted - 1 month ago

$PDD $PYPD $PDLI

Fredzel Posted - 1 month ago

$SLDB $PYPD

Tripel1 Posted - 1 month ago

$PYPD

TickerDD_com Posted - 1 month ago

From 2/26/2024, looking back across 22 Month-Ends for PYPD, Percentage Change of Average Monthly Price had More Negatives (68%) while Percentage Change of Average Monthly Volume had All Positives (100%) $PYPD #PYPD #PYPDStock #TickerDD #PYPDPrice https://www.youtube.com/watch?v=vQZqJxAyfNE

Fredzel Posted - 1 month ago

$PYPD $JAGX

_StockTrader Posted - 02/28/24

Real-Time Stock Data $PYPD Price: 5.89 Volume: 7101 Market Cap: 28543636 PE Ratio: -2.5105486 Stock data provided by: AITX

Stock_Titan Posted - 02/28/24

$PYPD PolyPid to Participate in Barclays 26th Annual Global Healthcare Conference https://www.stocktitan.net/news/PYPD/poly-pid-to-participate-in-barclays-26th-annual-global-healthcare-tvanplt3li9j.html

sxpl Posted - 1 month ago

$ICU $IOVA $PYPD https://www.tradingview.com/news/zacks:8a445def5094b:0-polypid-ltd-pypd-upgraded-to-buy-what-does-it-mean-for-the-stock/

Fredzel Posted - 1 month ago

$CPOP $MNPR $PYPD

kshonstocks Posted - 1 month ago

$PYPD "We are thrilled with the significant progress recently achieved throughout our business," stated Dikla Czaczkes Akselbrad, PolyPid's Chief Executive Officer. "As we expected, enrollment in our ongoing SHIELD II Phase 3 pivotal trial for D-PLEX100 has begun to ramp up, and we continue to anticipate top-line results from this study in the second half of 2024. We have also generated new highly compelling preclinical data with OncoPLEX that demonstrate its potential in oncology and beyond." https://investors.polypid.com/news-releases/news-release-details/polypid-provides-corporate-update-and-reports-fourth-quarter-1

kshonstocks Posted - 1 month ago

like $PYPD long idea interesting chart and solid recent ceo comments group is A+ ibd

Fredzel Posted - 2 months ago

$SNCR $VVOS $PYPD

DonCorleone77 Posted - 2 months ago

$PYPD PolyPid reports Q4 EPS ($3.97), consensus ($3.58) "We are thrilled with the significant progress recently achieved throughout our business," stated Dikla Czaczkes Akselbrad, PolyPid's Chief Executive Officer. "As we expected, enrollment in our ongoing SHIELD II Phase 3 pivotal trial for D-PLEX100 has begun to ramp up, and we continue to anticipate top-line results from this study in the second half of 2024. We have also generated new highly compelling preclinical data with OncoPLEX that demonstrate its potential in oncology and beyond."

epsguid Posted - 2 months ago

$PYPD reported a loss of $3.97, consensus was ($2.17) via @eWhispers #epsmiss http://eps.sh/d/pypd

Stock_Titan Posted - 2 months ago

$PYPD PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results https://www.stocktitan.net/news/PYPD/poly-pid-provides-corporate-update-and-reports-fourth-quarter-and-jy9bt4kyfh6k.html

DonCorleone77 Posted - 2 months ago

$PYPD PolyPid enrolls 100th patient in SHIELD II phase 3 trial PolyPid announced that it has enrolled and randomized the 100th patient in its ongoing SHIELD II Phase 3 trial for D-PLEX100 for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery with large incisions. There are currently approximately 40 centers open. The Company intends to conduct an unblinded interim analysis once a total of approximately 400 patients complete their 30-day follow-up, which is expected to occur in mid-2024. "As anticipated, since last November, we have doubled the number of open centers, and enrollment into SHIELD II has recently begun to ramp-up," said Dikla Czaczkes Akselbrad, PolyPid's Chief Executive Officer. "We continue to expect top-line results from SHIELD II in the second half of 2024."

Stock_Titan Posted - 2 months ago

$PYPD PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 Trial https://www.stocktitan.net/news/PYPD/poly-pid-announces-enrollment-of-the-100th-patient-in-the-ongoing-uws0pxar3fmh.html

CHRCHR Posted - 2 months ago

$PYPD https://m.au.investing.com/news/stock-market-news/polypid-to-unveil-q4-and-2023-fullyear-financials-on-feb-14-93CH-3101538

sxpl Posted - 2 months ago

$RVSN $PYPD 🇮🇱 Israel 🇮🇱 🫵👍🏽

DonCorleone77 Posted - 2 months ago

$PYPD PolyPid files to sell 6.74M ordinary shares for holders